X
More than 60,000 patients use Brite
4.6 stars
Your health finally understandable with Brite
Enter email and you're done. No subscription, no credit card.
Search, tap and you're done. Over 3,400 medicines.
Check, remind, get an overview.
Sarah K., 34
I finally understand my therapy. The app reminds me, answers my questions — and I don't feel alone with it anymore.
Escitalopram has become the first-line antidepressant for many mental health professionals. It is the pure, effective S-enantiomer of citalopram and offers the same — or even better — effectiveness at half dose with potentially fewer side effects.
See more detail.gif)
Never stop escitalopram suddenly – always taper over weeks. This article does not replace psychiatric advice. If you have suicidal thoughts: Telefonseelsorge 0800 111 0 111 (free, 24/7; in the UK, Samaritans 116 123).
Escitalopram is today the most prescribed antidepressant in Germany and is regarded among psychiatrists as the first-choice agent for depression and anxiety disorders. It is the pharmacologically "purified" successor to citalopram – the same effect at half the dose, less QT risk, broader approval. One important feature: escitalopram is broken down via the liver enzyme CYP2C19, which is also inhibited by omeprazole. Anyone taking both has higher escitalopram levels in the blood – with an increased QT risk.
| Property | Details |
|---|---|
| Active substance | Escitalopram (S-enantiomer of citalopram) |
| ATC code | N06AB10 |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Available forms | Film-coated tablets 5 / 10 / 15 / 20 mg; drops |
| Half-life | Approx. 27–32 hours |
| Bioavailability | Approx. 80% |
| Metabolism | CYP2C19 + CYP3A4 (caution: omeprazole!) |
| Intake | Once daily, independent of meals |
| Onset of action | 2–4 weeks |
| Prescription status | Yes |
| Equivalent dose | 10 mg escitalopram ≈ 20–40 mg citalopram |
This is by far the most common question about escitalopram – and the pharmacological answer is elegant. Citalopram consists chemically of two mirror-image molecules: the R-enantiomer and the S-enantiomer. This 50:50 mixture is called a racemate. The problem: only the S-enantiomer is antidepressant-active. The R-enantiomer barely contributes to the effect but is partly responsible for the QT prolongation. Escitalopram is the isolated, pure S-enantiomer – so the active molecule has been extracted and the inactive part left out.
The result: 10 mg escitalopram works comparably to 20–40 mg citalopram – with less QT prolongation and a broader approval for five indications instead of two. The Cipriani meta-analysis in the Lancet (2009) additionally showed a slight efficacy advantage of escitalopram over other SSRIs. For patients who currently take citalopram and cope well with it, there is no compelling reason to switch. For new starts, however, escitalopram is today clearly preferable.
| Escitalopram | Citalopram | |
|---|---|---|
| Chemistry | Pure S-enantiomer | Racemate (R+S mixture) |
| Active fraction | 100% | Approx. 50% (only the S-fraction) |
| Standard dose | 10 mg | 20 mg |
| Maximum dose | 20 mg (10 mg in older people) | 40 mg (20 mg in older people) |
| QT prolongation | Lower (4.3 ms at 10 mg) | Greater (10–20 ms) |
| Approvals | 5 indications | 2 indications |
| Cipriani 2009 meta-analysis | Slight efficacy advantage | No advantage |
| CYP interaction potential | Similar (CYP2C19) | Somewhat higher |
| Price (generics) | Comparable | Comparable |
Escitalopram selectively blocks the serotonin transporter (SERT) – the protein that takes serotonin back up into the sending nerve cell after release. Through the blockade, serotonin remains longer in the synaptic cleft and stimulates the downstream receptors more intensely. Serotonin activity in the brain rises – which has a mood-lifting, anxiety-relieving, and drive-increasing effect.
As with the related citalopram: the rise in serotonin happens immediately, but the actual antidepressant effect only arises through the slow desensitisation of the receptors – a process that takes 2–4 weeks. This explains why side effects can occur in the first few weeks without the mood having improved yet.
Escitalopram has five approved indications – considerably more than citalopram. One important dosing principle applies to all anxiety disorders: always start with 5 mg. Patients with panic disorder often react paradoxically at the start with increased anxiety. Anyone who starts with 10 mg may experience the therapy as unbearable and stop it – when it would have been well tolerated with a slower introduction.
| Indication | Starting dose | Standard dose | Maximum dose |
|---|---|---|---|
| Depression | 5–10 mg | 10 mg | 20 mg |
| Panic disorder | 5 mg (!) | 10 mg | 20 mg |
| Generalised anxiety disorder | 10 mg | 10 mg | 20 mg |
| Obsessive-compulsive disorder | 5–10 mg | 10–20 mg | 20 mg |
| Social phobia | 5–10 mg | 10 mg | 20 mg |
| Older people (>65 years) | 5 mg | 5–10 mg | 10 mg (!) |
| Hepatic impairment | 5 mg | 5–10 mg | 10 mg |
Escitalopram prolongs the QT interval on the ECG – less than citalopram, but clinically relevant enough for a Dear Doctor safety letter in 2011. The QT prolongation is dose-dependent: at 10 mg it is 4.3 ms – at supratherapeutic 30 mg it is 10.7 ms. The risk is thus considerably lower than with citalopram (10–20 ms), but an ECG at the start of therapy and in at-risk groups remains sensible.
The combination with electrolyte disturbances becomes particularly dangerous: a potassium deficiency caused by diuretics like torasemide, or a magnesium deficiency caused by long-term pantoprazole therapy, considerably amplifies the QT risk. Anyone taking escitalopram together with a diuretic or a PPI should have their electrolytes checked regularly.
| Risk group | Recommendation |
|---|---|
| Pre-existing long-QT syndrome | Contraindicated! |
| Older people > 65 years | Max. 10 mg, ECG recommended |
| Hepatic impairment | Max. 10 mg |
| QT-prolonging co-medication (macrolides, antipsychotics) | Contraindicated! |
| Hypokalaemia / hypomagnesaemia | Normalise electrolytes first! Caution: torasemide / pantoprazole |
The side effects of escitalopram follow a predictable pattern – and anyone who knows this pattern does not stop the therapy prematurely.
In the first 1–2 weeks, adjustment reactions dominate: nausea, inner restlessness, sleep disturbances, and headaches. These symptoms arise because the brain reacts to the sudden rise in serotonin and has to adjust. In most patients they disappear by themselves after 1–2 weeks. Anyone who suffers from nausea should take escitalopram with food – this reduces irritation of the stomach lining.
From the second week, the mood begins to lift, the anxiety eases, drive returns. The initial side effects fade. A doctor's appointment in this phase makes sense, to evaluate the dose – in some patients 10 mg is enough long-term, others need an increase to 20 mg.
Sexual dysfunction and emotional blunting are the most common long-term complaints and are rarely raised spontaneously. Emotional blunting – the feeling of properly experiencing neither joy nor sorrow – is felt by some patients to be worse than the original depression. Sweating, especially at night, is also common and often persistent. All of these long-term side effects should be raised actively with the doctor – there are options (dose reduction, switching to bupropion or vortioxetine).
40–70% of all SSRI users develop sexual dysfunction – making it the most common side effect, yet the one most rarely raised. Loss of libido, delayed ejaculation, anorgasmia, and erectile dysfunction can affect any patient, regardless of age and sex. The problem is often kept quiet because the topic is uncomfortable or because patients assume it is simply "a consequence of the treatment".
That is wrong. There are several strategies: a careful dose reduction often helps – if the depression stays stable with it. Switching to bupropion (not an SSRI, barely any sexual side effects) or vortioxetine can be sensible. Mirtazapine also has fewer sexual side effects but often causes weight gain. The most important step: raise the topic with the doctor. Sexual side effects are rarely asked about actively in doctor's consultations – patients have to bring the topic up themselves.
A phenomenon to be taken seriously, rare but real: in a small proportion of patients, sexual dysfunction persists even after stopping escitalopram – sometimes over months or years. This so-called Post-SSRI Sexual Dysfunction (PSSD) is scientifically documented and was recognised by the EMA in 2019. The mechanism is not yet fully understood. The risk is rare, but every patient who takes SSRIs should know about it – and should see a doctor if complaints persist after stopping.
Stopping escitalopram is for many patients the most difficult part of the entire treatment. Abrupt stopping leads, in a considerable proportion of patients, to discontinuation symptoms – brain zaps, dizziness, nausea, irritability, and sleep disturbances. This is not because escitalopram is addictive, but because the brain has adapted to the raised serotonin level and needs time to recalibrate.
The mechanism is the same as with citalopram: the serotonin-transporter blockade does not behave linearly with the dose. The step from 5 mg to 0 mg is pharmacologically more dramatic than from 20 to 10 mg – because the last milligrams account for a disproportionately large share of the transporter blockade. That is why the last step in particular must be taken slowly. Drops allow doses of 2–3 mg and are very valuable in this phase.
| Phase | Dose | Duration |
|---|---|---|
| Phase 1 | 20 mg → 15 mg | 2–4 weeks |
| Phase 2 | 15 mg → 10 mg | 2–4 weeks |
| Phase 3 | 10 mg → 5 mg | 2–4 weeks |
| Phase 4 | 5 mg → stop | 2–4 weeks |
| Phase | Dose | Duration |
|---|---|---|
| Phase 1 | 10 mg → 5 mg | 2–4 weeks |
| Phase 2 | 5 mg → stop (or 5 mg every other day) | 2–4 weeks |
